

Most Read This Week
- Predicting Disease Recurrence, Progression, and Overall Survival Following Surgical Resection for High-Risk RCC
- Clear Cell RCC
- Nivolumab Plus Cabozantinib Improves Outcomes in Advanced RCC
- Lenvatinib and Pembrolizumab Compared to Sunitinib for Advanced Renal Cell Carcinoma
- Circulating Cytokines Associated With Clinical Response to Systemic Therapy in Metastatic RCC
Recently Updated
- Poorer Baseline Performance Status Is Associated With Increased VTE Risk in Metastatic Cancer Patients Treated With Immunotherapy
- Pegilodecakin as Monotherapy or in Combination With Anti–PD-1 or TKI in Heavily Pretreated Patients With Advanced RCC
- Circulating Cytokines Associated With Clinical Response to Systemic Therapy in Metastatic RCC
- Predicting Disease Recurrence, Progression, and Overall Survival Following Surgical Resection for High-Risk RCC
- Clear Cell RCC